Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In relapsed ovarian cancer, systemic treatment has been the standard of care. However, recent studies, such as the Desktop III study, have indicated that cytoreductive surgery followed by chemotherapy can lead to longer overall survival compared with chemotherapy alone.1 These findings may result in more patients choosing surgery as a treatment option for relapse. In cases of local relapse of advanced epithelial ovarian cancer, surgical treatment often involves sigmoid resection, with the possibility of primary reanastomosis.2
This case involves a woman diagnosed in 2018 with high-grade serous adenocarcinoma, characterized by positive peritoneal washing cytology. She underwent a complete staging surgery for early-stage ovarian cancer, which included laparoscopic sigmoidectomy with a ghost ileostomy.3 The final International Federation of Gynecology and Obstetrics (FIGO) stage was identified as high-grade serous carcinoma FIGO IC3. After undergoing surgical treatment, the patient underwent four cycles of adjuvant chemotherapy. However, during a follow-up scan, 4 years later, a 4 cm tumor was detected in the mid-superior rectum, confirming the presence of a local relapse. Consequently, it was decided to proceed with secondary cytoreductive surgery to address the relapse of ovarian cancer.
This case highlights the potential benefits of using a laparoscopic approach to achieve satisfactory oncologic outcomes while minimizing the post-operative risks and delays in adjuvant treatments. Performing surgical intervention during the relapse of advanced ovarian cancer has been proved to significantly enhance oncologic outcomes, particularly by prolonging progression-free survival and overall survival rates. It is worth highlighting that surgical intervention does not adversely impact the quality of life of patients, ensuring that their overall well-being is not compromised. The positive impact of surgery for improved oncologic outcomes and the maintenance of a satisfactory quality of life makes it a valuable and beneficial option for individuals experiencing relapse in advanced ovarian cancer. In addition, minimally invasive surgery is equally effective as laparotomy in ensuring disease-free survival for women diagnosed with advanced-stage epithelial ovarian cancer who have positively responded to neoadjuvant chemotherapy.4 5 This case presentation was carried out with informed consent and ensuring preservation of the patient’s anonymity.
Patient consent for publication
Contributors PP-I: Conceptualization, project administration, surgery, video recording, supervision, writing – review.
MM-A: Guarantor, conceptualization, video editing, writing - original draft.
MA: Conceptualization, project administration, supervision, surgery, and writing – review.
VL: Conceptualization, project administration, supervision, writing – review.
MF: Conceptualization, project administration, surgery, supervision, writing – review.
LM: Conceptualization, project administration, surgery, supervision, writing – review.
SD: Conceptualization, project administration, supervision, writing – review.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.